COMMUNIQUÉS West-GlobeNewswire

MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
01/05/2026
Enrollment completed in ML-007C-MA’s ZEPHYR Phase 2 trial in schizophrenia Last patient visit completed for ML-004’s IRIS Phase 2 trial in autism spectrum disorder Topline results from both Phase 2 trials expected by [...]
Pluristyx and Qkine Announce a Reciprocal Distribution Agreement in Support of Optimized Growth Factor Differentiation of Induced Pluripotent Stem Cell (iPSC)
01/05/2026
SEATTLE and CAMBRIDGE, United Kingdom, May 01, 2026 (GLOBE NEWSWIRE) -- Pluristyx, a leading provider of clinical-grade induced pluripotent stem cell (iPSC) solutions, and Qkine, a pioneer in the manufacture of high- [...]
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
01/05/2026
-- First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity -- -- European Commission grants authorization in adults and children 4 years of age and above with acquired hypothalamic obesity [...]
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution
01/05/2026
HEMANGEOL is now available exclusively through Anovo Specialty Pharmacy to streamline access and therapy initiation Eton has integrated full Eton Cares patient support, including $0 co-pay for eligible commercially [...]
BrightSpring Health Services, Inc. Reports First Quarter 2026 Financial Results and Increases Full Year 2026 Guidance
01/05/2026
LOUISVILLE, Ky., May 01, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex [...]
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
01/05/2026
Latest findings from the DME AWARE Delphi Study on unmet needs in diabetic macular edema (DME) management highlighting the need for non-invasive therapeutic options to be presented by Baruch Kuppermann, M.D., Ph.D. New [...]
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
01/05/2026
ZUG, Switzerland, May 01, 2026 (GLOBE NEWSWIRE) -- Latest findings from the DME AWARE Delphi Study on unmet needs in diabetic macular edema (DME) management highlighting the need for non-invasive therapeutic options to [...]
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026
01/05/2026
Tokyo, Japan and Cambridge, UK, 1 May 202 6 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March [...]
MemoPryl Under Investigation (2026 Official Website Scam WARNING Update) Avoid Fake Complaints & Hidden Risks
01/05/2026
MemoPryl Scam Warning Explained: Nootropic Ingredients, Official Website Pricing, and 60-Day Refund Policy — 2026 Consumer Verification Update Aurora, CO, April 30, 2026 (GLOBE NEWSWIRE) -- These statements have not [...]
Senseonics Announces Pricing of $80 Million Public Offering of Common Stock and Pre-Funded Warrants
01/05/2026
GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable [...]
SteelPower Capsules for Male Enhancement Support: Review the Ingredients & Where to Buy to Avoid Complaints
01/05/2026
SteelPower Ingredient Label, Pricing, and Official Availability Explained for Men Researching Male Performance Support Supplements Aurora, CO, April 30, 2026 (GLOBE NEWSWIRE) -- These statements have not been evaluated [...]
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock
01/05/2026
AUSTIN, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for [...]
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
01/05/2026
NEW YORK & TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline on April 28, 2026, by Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP), please note references to Veterans Exploring [...]
Leanzene Gummies Under Investigation (2026 Official Website Scam WARNING Update) Avoid Fake Complaints & Hidden Risks
01/05/2026
Leanzene Gummies Scam Warning Explained: ACV and BHB Ingredients, Official Website Pricing, and 60-Day Money-Back Policy — 2026 Update Aurora, CO, April 30, 2026 (GLOBE NEWSWIRE) -- These statements have not been [...]
Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering
01/05/2026
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of [...]
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
01/05/2026
The Company reported over NIS 270 million in revenue, NIS 37 million in Net loss, NIS 47 million in Adjusted EBITDA and NIS 17 million in positive operating cash flow, reflecting strong resilience and consistent [...]
Totus Medicines to Present Interim Phase 1b Clinical Data for TOS-358 + Fulvestrant Doublet Therapy in HR+/HER- Breast Cancer Patients at ESMO Breast Cancer Annual Congress 2026
01/05/2026
TOS-358 is a covalent, pan-mutant, α-specific PI3K inhibitor designed to address key limitations of existing PI3Kα therapies which include limited mutation coverage and poor tolerability Data will include efficacy, [...]
YD Bio Limited Reports Full Year 2025 Financial Results
01/05/2026
TAIPEI, Taiwan, April 30, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic [...]
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
30/04/2026
On track for first patient dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers in Q2 of 2026 HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a [...]

Pages